What kind of disease is Huntington's chorea - causes, symptoms

From the history of the disease

Since the classic symptoms of chorea are erratic arm movements and an unsteady gait accompanied by dancing movements, it is not surprising that the Greek word chorea, which means “dance,” eventually became the name for this disease.

One of the first doctors to describe this serious illness was Paracelsus (1493-1541). Describing the phenomena of religious ecstasy in the form of the dance of St. Vitus, popular in the Middle Ages and the Renaissance, he discovered people demonstrating severe pathological symptoms. Much later, already in the 17th century, the doctor T. Sydenham described chorea, which appears in childhood and was named in his honor. And only in 1872, D. Huntington (Huntington) described a hereditary form of chorea that debuts in adults. Now this disease is called chorea or Huntington's disease (abbreviated as HD).

In 1993, an international team of genetic researchers discovered a mutation that causes HD.

Pathogenesis

It has been proven that Huntington's chorea develops as a result of an increase in the number of trinucleotide repeats - cytosine-adenine-guanine, located in the first exon of the gene. The cytosine-adenine-guanine triplet encodes the amino acid glutamine, so an elongated polyglutamine tract is formed in the protein. Forming something like a zipper, the extended polyglutamine region of the huntingtin protein changes its own information and binds tightly to other proteins. As a result, protein aggregation occurs, protein-protein interactions are disrupted, which leads to cell apoptosis.

Causes of chorea

We are talking about serious genetic changes: this is the HNT gene, which is responsible for the development of pathology. Its location is the fourth chromosome. It has the ability to encode a special protein called huntingtin. How it works normally is unknown to science, but if it changes due to genetic abnormalities, HD occurs.

As the protein changes its structure, it causes nerve cells in the human brain to begin to function incorrectly and eventually die. Huntingtin is a complex substance, so the course of the disease is complex and multivariate. Modern researchers continue to actively study Huntington's chorea, trying to better understand the specifics of the basic mechanisms of its development.

The mutation that causes chorea is contained in all cells of the patient’s body, so we are talking about a classic hereditary disease.

Huntington's disease

Symptoms and treatments

Huntington's Disease

(David Rubinsztein, Serious Science). Translation: PostScience.

Huntington's disease (also Huntington's disease) is a devastating autosomal dominant neurodegenerative disorder. The chances that a carrier will pass it on to one of their children are 50%.

Huntington's disease is one of the most common neurological diseases caused by a single gene mutation. The features of this disease - deposits of protein aggregates in nerve cells - are characteristic of Alzheimer's disease and Parkinson's disease.

Image of the disease process - a neuron affected by inclusion bodies // wikipedia.org

Causes of Huntington's disease

Huntington's disease is caused by a trinucleotin CAG repeat expansion in the gene encoding the huntingtin protein. Healthy people have fewer than 36 CAG repeats, the sequence looks like this: CCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG... People with Huntington's disease have 36 or more of these repeats. When CAG repeats are translated into the amino acid glutamine, mutant huntingtin develops an abnormally long polyglutamine tract. This type of mutation is seen in eight other neurodegenerative diseases.

An extended polyglutamine tract imparts toxic properties to huntingtin. They may be due to the mutant protein's tendency to aggregate or because the mutant huntingtin interferes with the normal functioning of other proteins in the cell. This leads to neurodegeneration, especially noticeable in the caudate nucleus, putamen and cerebral cortex.

Symptoms of Huntington's disease: chorea

At the clinical level, the patient exhibits abnormal chaotic movements, decreased cognitive abilities (a form of dementia), and psychiatric abnormalities. The most obvious movement disorder seen in Huntington's disease is called chorea - abnormal short and irregular uncontrolled movements. Psychiatric symptoms of illness, such as depression, are partly related to the biology of the disease and are not always the patient's response to its presence.

Huntington's disease usually appears in midlife, around age 40. However, in cases with a very high number of repeats, the disease may appear in early childhood. In some cases, when the number of CAG repeats is close to 36, the disease manifests itself towards the end of life. The longer the chain of trinucleotide repeats, the earlier signs of the disease appear. Symptoms of the disease are similar in all patients, although there may be some differences at the initial stage. The disease continues for 15–20 years until the death of the patient.

History of Huntington's disease research

The disease is named after the American physician George Huntington, who described it in detail in 1872. “On Chorea” was the first of two articles by Huntington, in which he carefully described the symptoms of the disease that he observed in a family living on Long Island.

However, there are earlier descriptions of Huntington's disease. James Guzella first made the connection between the disease-causing gene and the short arm of the fourth human chromosome. This is the first classic example of how the location of a gene on a specific part of a chromosome can be discovered based on the study of families. Guzella and a large consortium's subsequent identification of the disease-causing mutation and gene enabled further precise genetic testing and provided a key resource for modeling the disease in cells and animals, which is critical for developing treatments.

Treatment of Huntington's disease

There is currently no known treatment to alleviate human neurodegeneration, but tetrabenazine may improve some movement disorders. Tetrabenazine is not thought to reduce the level of neurodegeneration in Huntington's disease. Chorea is caused by an excess of the neurotransmitter dopamine, tetrabenazine reduces its activity and reduces the symptom.

Numerous treatments are currently being developed to treat Huntington's disease at the mechanistic level. These include strategies to reduce mutant protein expression using antisense techniques (in clinical trials) and activation of autophagy. Antisense strategies involve nucleic acid oligonucleotides. They have sequences complementary to the Huntington's disease gene and reduce the amount of huntingtin synthesized. This strategy is quite rational, since the main driver of the disease is mutant huntingtin.

Prevalence of Huntington's disease

The disease affects 1 in 10,000 people in populations of European ancestry. Most often, Huntington's disease occurs in population isolates (in Venezuela), less often in some populations (for example, in the Japanese). Differences in the prevalence of the disease in populations are associated with the number of carriers of the gene in these groups. This is a consequence of historical events, including random increases or decreases in Huntington's disease carriers in population isolates.

The protective role of autophagy

In the laboratory, we have focused on the protective functions of autophagy in Huntington's disease and related neurodegenerative conditions. Autophagy is a process in which the internal components of a cell are delivered into its lysosomes or vacuoles and undergo degradation in them.

We found that intracellular aggregation-prone proteins (like mutant huntingtin) are substrates of autophagy. Importantly, we were the first to show that drugs that stimulate autophagy also stimulate the removal of toxic proteins. These are mutant huntingtin, mutant ataxin-3 (causing the most common spinocerebellar ataxia), alpha-synuclein (in Parkinson's disease), and wild-type and mutant tau proteins (associated with Alzheimer's disease and various types of frontotemporal dementia).

We have expanded our research from cellular systems to demonstrating the effectiveness of such drugs in disease models in fruit flies, zebrafish, and mice. This concept was subsequently confirmed by many research groups in various neurodegenerative diseases.

Our challenge is to develop this strategy into clinical reality. We have conducted a number of studies to identify new drugs that induce autophagy. My colleague Dr. Roger Barker and I have completed testing one of the identified drugs in patients with Huntington's disease.

Protein aggregate in the mouse brain (marked with arrows) // serious-science.org

Studying the functions of huntingtin and modern therapy

There are many ongoing research projects that are contributing to the study of the disease. First, the most active question being explored is how mutant huntingtin causes disease. To answer this, we need to use methods from structural biology, biophysics, genetic scanning, cell biology and animal models. Some groups are focusing on studying the disease at the biochemical level, trying to understand the structure of the mutant protein and its early aggregating species. Others are using cellular, neural, and stem cell models to understand what the mutant protein does. They are complemented by studies on animals: worms, fruit flies, zebrafish, mice, rats and even primates and sheep. This is necessary to develop models that will allow us to understand the disease at the organism level. Therapeutic strategies can be tested in such models.

Secondly, we need to understand what the functions of normal huntingtin are - they are poorly understood. To shed light on these functions, research groups are using different approaches based on cellular modeling. This could impact therapeutic strategies and/or our overall understanding of how the cell works.

The third goal is to identify potential therapeutic targets for disease relief and improve existing treatment strategies. Various research groups are working on this issue; they use chemical and genetic scanning techniques to identify new targets and drug candidates.

The fourth goal is to identify and characterize biomarkers of disease progression to facilitate clinical trials. This will make it possible to track the benefits of any therapeutic strategy. It would be useful to have a very sensitive scale of disease progression with a short time interval. This is important for those who are carriers of the gene for the disease, but do not yet have obvious signs and symptoms. In this case, it will be possible to test the effects of potential therapeutics that slow the progression of the disease.

About the author: David Rubinstein – Professor of Molecular Neurogenetics; Deputy Director, Cambridge Institute for Medical Research.

Portal “Eternal Youth” 04/21/2017

Symptoms of chorea

The time of appearance of the first symptoms of chorea is middle age (period from 35 to 55 years). About 10% of clinical cases of HD occur in childhood and adolescence. In such situations, experts talk about juvenile chorea.

The development of the disease often occurs latently and is unnoticeable at first, so it can be diagnosed late.

The symptoms of chorea are varied. For example, it can manifest itself with a combination of symptoms (the patient’s mood constantly changes and difficulties in thinking arise). The development of symptoms depends on age and severity of the pathology. Some patients demonstrate predominantly motor disorders with mild mental disorders, while others, on the contrary, show anxiety, signs of depression or other mental disorders. The exact time when the first symptoms appear is difficult to determine.

Diagnostics

A neurological examination of the patient and analysis of the clinical picture allows a preliminary diagnosis to be made. Much attention is paid to family history (presence of similar symptoms or confirmed chorea in close relatives), medication use, previous infectious diseases, etc.

For a final conclusion, a comprehensive medical examination is required. General and biochemical blood tests can detect inflammation, determine the level of copper and ceruloplasmin in the blood, and also detect liver particles indicating Wilson-Konovalov disease.

Additionally, CT or MRI and electroencephalography are prescribed.

Differential diagnosis is also carried out with acute rheumatic fever, athetosis, dystonia, myoclonus, athetosis.

Movement disorders

Movement disorders associated with chorea are usually called:

• actually, trochee;
• bradykinesia;
• dystonia.

These symptoms prevent the patient from being in a natural physiological position, disrupting the processes of walking and balance. “Dance” is expressed in involuntary movements that a person cannot control. Bradykinesia manifests itself in the slowness and complexity of voluntary movements, and dystonia manifests itself in the formation of unnatural and awkward poses, accompanied by “twisting” or twitching of the limbs. Also, movement disorders that occur with Huntington's chorea include dysfunction of the eye muscles, problems with swallowing and unclear speech.

Motor disturbances in the manifestations of chorea in adults are characterized by speed, pretentiousness and spontaneity. In this case, any muscle groups can be involved, and control of movements is absolutely impossible.

Usually, the onset of a pathological process is indicated by deviations observed during movements of the facial muscles. Patients grimace, stick out their tongues, raise their cheeks, curl their lips into a “tube,” frown and wink ridiculously. The progression of the pathology is accompanied by the appearance of involuntary movements in other muscles. Patients begin to quickly bend and straighten their fingers, then similar symptoms affect the lower extremities. Sometimes movements occur in the legs and arms at the same time.

Children suffering from chorea, on the contrary, demonstrate sluggish movements. They are very slow, and the child’s speech is slurred, with incorrect pronunciation of sounds and words, impaired speed and rhythm. From the motor sphere, oscillatory movements of the eyeballs are typical. The child cannot normally move his gaze from one object to another and focus his vision on a specific object.

When the disease begins in childhood and adolescence, experts note bradykinesia and muscle stiffness as the main symptoms. Children do not demonstrate violent movements, as with classical chorea in adults. Also, juvenile chorea is characterized by disturbances in behavior and learning with rapid progression of the entire symptom complex.

When the disease begins in a later age, chorea itself is its leading symptom, and its heredity is very easy to identify. Most often, the parents of an adult patient are no longer alive, since they simply do not live to see the moment when their offspring begin to experience severe symptoms of chorea.

Free consultation on training issues

Our consultants are always ready to tell you about all the details!

Signs of Huntington's chorea in adults

“The disease usually manifests itself in the 3rd to 5th decade of life,” explains neurologist Valentina Kuzmina. – Initially, it makes itself felt with barely noticeable signs, but gradually manifests itself in the form of generalized choreic hyperkinesis, namely:

• the presence of obsessive pretentious movements;
• speech impairment;
• memory impairment;
• emotional and personality disorders.

Chorea usually begins in the face or distal extremities (fingers or toes), then gradually spreads and impairs voluntary movements.
Patients cannot hold their tongue out for a long time or clench their hand in a fist. The gait becomes unstable, “dancing”, slow and tense. Speech is difficult to understand, unclear, blurred. Later, dysphagia develops (impaired swallowing of food and water), which causes aspiration (choking and food entering the bronchi), leading to suffocation and pneumonia. Urinary incontinence also appears.

The ability of the gene to manifest itself is close to 100% - by the age of 70, the disease manifests itself in almost all its carriers. Such patients become disabled.

Mental changes

The psyche in HD undergoes gradual pathological changes. A decrease in a person’s ability to fully think is characterized, first of all, by problems with memory and a decrease in the critical threshold for perceiving one’s own state. The patient becomes anxious, irritable or, conversely, apathetic. In severe cases, hallucinatory or delusional syndromes develop. Suicidal behavior is also common in the context of severe depression.

Also, the following mental symptoms may appear:

• aggressive outbursts;
• insomnia;
• impulsiveness and spontaneity in behavior;
• social alienation.

Delusions and hallucinations are much less common. As for mental disorders, as the disease progresses, patients gradually lose memory acuity, logic and concentration. They find it difficult to make independent decisions and give clear answers to even the simplest questions. Over time, they learn new information worse and worse, which is an obvious sign of progressive dementia.

Conclusion: synaptic transmission disorders and neurodegenerative diseases

The study confirmed our initial guess: disruption of the striatum in HD is associated primarily with disruption of synaptic transmission. The striatum neurons stop “hearing” the commands of the cortical neurons, and, as a result, the person begins to lose control over his movements. But at an early stage of the disease, these disorders are functional in nature and are probably reversible. If we find out the reasons leading to disruption of synapses, then it is possible to develop a drug that will help stop pathological changes, provide striatal neurons with the necessary level of activation and, thus, prevent the development of irreversible morphological disorders.

The results of this work also lead to another important conclusion: when studying neurodegenerative diseases, scientists should pay more attention to synaptic transmission and the interaction of neurons. We know quite a lot about how the accumulation of amyloid aggregates in Alzheimer's disease affects cell activity, and which neurons die during the development of Parkinson's disease, but this has still not led to the emergence of effective therapy. A possible reason for these failures is that we do not take into account the consequences of disruption of synaptic connections - those that we discovered in the study of Huntington's disease. We hope that our findings will point researchers in the direction of developing effective treatments for Huntington's disease, and Thirteen will finally be healthy!

The study was carried out in the laboratory of molecular neurodegeneration of St. Petersburg State Polytechnic University (head of the laboratory - Prof. Ilya Borisovich Bezprozvanny, University of Texas) under the guidance of Ph.D. Dmitry Nikolaevich Artamonov.

Stages of flow

Dr. A. Scholsen from Georgetown University (USA) proposes five stages of chorea development as a classification:

• early The patient has been diagnosed with Huntington's chorea, but so far his full functions have not been impaired;
• intermediate early. A person is able to work and have normal contact with society, but difficulties in thinking, movement and behavior are already making themselves felt. Patients can still cope with everyday activities and work;
• intermediate late. The patient is no longer able to work, but he still does household chores himself;
• late initial. The patient loses independence, but at home retains a number of functions - subject to the regular participation of other people in his daily life;
• late. Help is needed all the time, including professional care. Note that the late stage of the disease requires a special approach and skills from the people around the patient.

Folk remedies

Photo: beardoholic.com

Chorea is a serious disease that requires medical attention. Under no circumstances should one assume that folk remedies can save a person from this illness. As was written earlier, sedatives are used in the treatment of chorea. Many of them are based on plant components. Therefore, they can be safely replaced with traditional medicine.

There are many folk recipes that have a sedative effect:

• Infusion of oregano, calendula and tansy. To prepare a soothing mixture, you will need to mix the listed herbs in equal quantities, pour boiling water over it, wrap it up and let it brew for at least half an hour. After preparation, the infusion is used three times a day, 100 ml. For one glass of boiling water you will need 1 tablespoon of the mixture.
• An infusion of lemon balm leaves is also easy to prepare. To do this, you will need 3 tablespoons of crushed lemon balm leaves, which are poured with a glass of boiling water and simmered in a water bath for 10 - 15 minutes. After which the infusion should be cooled and strained. You need to consume 100 ml twice a day.

It’s even easier to make lemon balm tea, which is no less beneficial than the infusion.

Mint is very popular, and many people grow it in their summer cottage. To prevent such a wonderful herb from going to waste, you can brew tea using it. This tea will not only improve your mood and relieve irritability, but also help you fall asleep quickly.

There is another sedative based on honey and beet juice. To prepare it, you need to mix beet juice and honey in half. The resulting mixture should be taken 0.5 cups 3 times a day for 10 days, after which a break is taken.

Herbal baths before bed are also effective. For example, to prepare one of them you will need 1 kg of herbs (wormwood, linden, rosemary). After mixing, the herb is poured with 4 liters of cold water, then boiled over fire for 5 minutes and infused for the next 15 minutes. After preparation, the resulting broth is filtered and poured into a warm bath.

The information is for reference only and is not a guide to action. Do not self-medicate. At the first symptoms of the disease, consult a doctor.

Forms of the disease

Based on the specifics of symptoms, the following forms of chorea are distinguished:

• hyperkinetic. It is characterized by spontaneous motor acts, which, as noted earlier, are not subject to conscious control. Also, speech disturbances due to hypertonicity of the facial muscles are typical for the hyperkinetic form of chorea. Sometimes patients have convulsions and uncontrolled oculomotor acts during sleep;
• akinetic-rigid. Severe muscle hypertonicity;
• mental. Dementia gradually develops, and the patient's personality undergoes destructive changes.

Psychotic phenomena for the latter form are also a characteristic feature.

Complications

Most forms of chorea are characterized by frequent relapses, the frequency of which can be reduced by following your doctor's recommendations.

When it comes to hereditary pathology, the prognosis is generally unfavorable. The disease gradually progresses. Severe complications develop - pneumonia, heart failure. Uncontrolled movements often cause injuries. Choreic hyperkinesis can cause spasm of the respiratory muscles, which can lead to suffocation. Patients often complain of hallucinations and other psychological disorders.

Non-drug treatment

In some cases, patients respond well to non-drug therapy in the form of:

• psychotherapeutic influence;
• exercise therapy;
• classes with a qualified speech therapist;
• breathing exercises;
• occupational therapy.

Regular use of these methods (of course, if the patient’s condition allows) can significantly reduce the intensity of pathological symptoms both physically and mentally. It has been proven that patients’ psycho-emotional background improves, they begin to better control their voluntary movements. Walking becomes more stable, as do swallowing and balance.

Physical exercise is one of the effective ways to slow down the development of movement disorders. There are special exercise therapy programs developed for such patients, which have repeatedly shown their effectiveness.

Models for studying Huntington's disease

Animal models of HD appeared more than 30 years ago. The first were models based on the introduction of neurotoxic substances into the striatum (for example, quinolinic acid, an NMDA receptor agonist), which caused neuronal death. Currently, most researchers are working on transgenic animal models, which include not only mice and rats, but also invertebrate animals - the fly Drosophila melanogaster and the worm Caenorhabditis elegans.

Mouse models of Huntington's disease differ from each other in the number of CAG repeats and the level of expression of the transgene - the artificially introduced huntingtin gene. Because The development of HD depends on these factors; different strains of mice differ from each other in the rate of development of pathologies. The most widely used models include the R6/2, R6/1, and YAC128 mouse strains, which were also used in our work. In mice of these lines, the symptoms of the disease are most pronounced and appear quite quickly. In addition, these animals develop cognitive and motor impairments with age and develop partial loss of neurons in the striatum and cortex.

Another way to model HD is to use cell culture. In the simplest case, cell cultures with stable transfection of the huntingtin gene are used. For example, these are PC12 cells containing an inducible transgene of the first exon of huntingtin or striatal neurons expressing huntingtin fragments of different lengths. In addition, primary cultures from neurons from transgenic mice or immortalized neurons can be used.

Drug treatment

Doctors use strong medication treatment in severe cases of chorea. One popular drug is tetrabenazine. It was developed specifically for the treatment of Huntington's chorea as a drug that reduces hyperkinesis.

Antipsychotics and drugs used for Parkinson's disease are also prescribed. The administration of antiparkinsonian drugs improves motor functions, and antipsychotics (for example, haloperidol, chlorpromazine, clozapine, etc.) alleviate the condition of patients with delusional and hallucinatory phenomena. If the patient is depressed, he is prescribed antidepressants; for insomnia, sedatives and sedatives are prescribed.

Forecast

The prognosis for this group of patients depends on the cause of choreic hyperkinesis. Thus, Huntington's chorea is an incurable disease, while Sydenham's chorea can be cured with antibiotics, chorea of ​​pregnant women usually resolves within 6 weeks after delivery, and metabolic and endocrine chorea disappear after the balance of factors in the body is normalized.

Whatever the cause of chorea, the doctor can develop the most appropriate treatment strategy for the patient.